Teva and Regeneron Pharmaceuticals have reported positive topline results from a Phase III study assessing the safety and efficacy of fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.
At week 16, the study met both co-primary endpoints and all key secondary endpoints.
Originally discovered by Regeneron, fasinumab is a fully human monoclonal antibody that targets Nerve Growth Factor, a protein that plays a key role in the regulation of pain signaling. Regeneron and Teva are jointly developing fasinumab as part of a global collaboration agreement. In Japan and 10 other Asian countries, Mitsubishi Tanabe Pharma Corporation holds exclusive development and commercial rights for fasinumab.
"We are encouraged by these data and look forward to advancing our pivotal Phase 3 fasinumab program in patients with osteoarthritis of the knee or hip, who currently have very limited therapeutic choices to treat their chronic pain, other than with non-steriodal anti-inflammatory drugs or opioids," said George D. Yancopoulos, M.D., Ph.D., President and Chief
Scientific Officer of Regeneron.
Read the press release